IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Anticancer Research

• Publication date

  2006-09-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  PMID 17094460
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.

  2006cited by this paper
• Interleukin‐10 and the immune response against cancer: a counterpoint

  2005cited by this paper
• Interleukin‐6 regulation of prostate cancer cell growth

  2005cited by this paper
• Inflammatory prostate cancer: an underestimated paraneoplastic clinical manifestation.

  2005cited by this paper
• Heat shock protein 90 (Hsp90) chaperone complex inhibitor, Radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor

  2005cited by this paper
• Interleukin-6 polymorphism is associated with more aggressive prostate cancer.

  2005cited by this paper
• Inhibitory effect of IL‐6‐induced neuroendocrine cells on prostate cancer cell proliferation

  2004cited by this paper
• Regulation of interleukin‐6‐mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells

  2004cited by this paper
• Immunohistochemical analysis of the IL‐6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate

  2004cited by this paper
• Interleukin-6 sequence variants are not associated with prostate cancer risk.

  2004cited by this paper
• Interleukin‐6 is responsible for drug resistance and anti‐apoptotic effects in prostatic cancer cells

  2004cited by this paper
• Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment

  2004cited by this paper
• Androgen Receptor Signaling

  2004cited by this paper
• Interleukin‐6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway

  2004cited by this paper
• Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 Cells.

  2004cited by this paper
• Expression and function of pro‐inflammatory interleukin IL‐17 and IL‐17 receptor in normal, benign hyperplastic, and malignant prostate

  2003cited by this paper
• IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R α chain in human primary prostate cancer cell lines

  2003cited by this paper
• Heat shock protein 90

  2003cited by this paper
• A novel IL-10 signalling mechanism regulates TIMP-1 expression in human prostate tumour cells

  2003cited by this paper
• Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

  2003cited by this paper
• Hsp90 as a therapeutic target in prostate cancer.

  2003cited by this paper
• Heat shock protein 90 as a molecular target for cancer therapeutics.

  2003cited by this paper
• Interleukin-6 is an autocrine growth factor in human prostate cancer.

  2001cited by this paper
• Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

  2001cited by this paper
• Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator

  2001cited by this paper
• The soluble interleukin 6 receptor: mechanisms of production and implications in disease

  2001cited by this paper
• Type 1 T regulatory cells

  2001cited by this paper
• Transforming growth factor-beta expression in prostate neoplasia.

  2000cited by this paper
• Cytokine variations in patients with hormone treated prostate cancer.

  2000cited by this paper
• Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue

  2000cited by this paper
• Heat shock protein-90, IL-6 and IL-10 in bladder cancer.

  2000cited by this paper
• Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice.

  1999cited by this paper
• Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes

  1999cited by this paper
• Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines.

  1995cited by this paper

• TGF-β1/TRAF-6 and IL-6/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer.

  2026cites this paper
• HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids.

  2024cites this paper
• Impacts of Interleukin-10 Promoter Genotypes on Prostate Cancer

  2024cites this paper
• Network pharmacology and transcriptomics reveal androgen receptor as a potential protein target for 6PPD-quinone.

  2024cites this paper
• Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).

  2024cites this paper
• A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer

  2023cites this paper
• The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors

  2022cites this paper
• Advances in the role of heat shock protein 90 in prostate cancer

  2022cites this paper
• High‐intensity interval training attenuates the effects caused by arterial hypertension in the ventral prostate

  2021cites this paper
• High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.

  2021cites this paper
• Heat shock protein 90α in thymic epithelial tumors and non-thymomatous myasthenia gravis

  2020cites this paper
• Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis.

  2020cites this paper
• Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition

  2020cites this paper
• Neoplasms of the Prostate

  2020cites this paper
• Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition

  2020cites this paper
• A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer

  2019cites this paper
• High level of interleukin-10 in serum after therapy is characteristic of prostate carcinoma patients with high Gleason score, high tumor volume and present peritumoral infiltration

  2019cites this paper
• Inhibition of Heat Shock Protein 90 as a Novel Platform for the Treatment of Cancer.

  2019cites this paper
• Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants *

  2018cites this paper
• Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants

  2018cites this paper
• Heat Shock Protein 90: Truly Moonlighting!

  2018cites this paper
• Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload

  2017cites this paper
• Immunohistochemistry Analysis for Interleukin-6 Expression from the Tumor Tissue

  2017cites this paper
• Investigation of Thermally Induced Cellular Ablation and Heat Response Triggered by Planar MoS2-Based Nanocomposite.

  2017cites this paper
• PSCA regulates IL‐6 expression through p38/NF‐κB signaling in prostate cancer

  2017cites this paper
• A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study

  2016cites this paper
• Steroid Receptor-Associated Immunophilins: A Gateway to Steroid Signalling.

  2015cites this paper
• Expression of proinflammatory cytokine interleukin-6 in tissue samples of human prostate obtained by needle biopsy.

  2015cites this paper
• Are androgen receptor variants a substitute for the full-length receptor?

  2015cites this paper
• Reducing the risk of prostate cancer with tomato and soy bioactives

  2015cites this paper
• Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: Association with asymptomatic inflammatory prostatitis NIH category IV

  2015cites this paper
• Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.

  2015cites this paper
• Combinatorial targeting of the androgen receptor for prostate cancer therapy

  2015cites this paper
• Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model.

  2015cites this paper
• The impact of inflammatory and immune response-related genetic variants on prostate cancer risk among men of African descent.

  2014cites this paper
• Inflammation and prostate cancer: the role of interleukin 6 (IL‐6)

  2014cites this paper
• Heat shock protein 90 is associated with hyperplasia and neoplastic transformation of canine prostatic epithelial cells.

  2014influential citation
• Celastrol Blocks Interleukin-6 Gene Expression via Downregulation of NF-κB in Prostate Carcinoma Cells

  2014cites this paper
• New Therapies in Hormone Relapsed Disease

  2014cites this paper
• Hsp90: still a viable target in prostate cancer.

  2013cites this paper
• Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

  2013cites this paper
• Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors

  2013cites this paper
• Compounds Targeting Androgen Pathways

  2013cites this paper
• Mini-review: Foldosome regulation of androgen receptor action in prostate cancer

  2013cites this paper
• Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation

  2013cites this paper
• Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

  2013cites this paper
• Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors

  2012cites this paper
• Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

  2012cites this paper
• Molecular Chemotherapy and Chemotherapy: A New Front against Late-Stage Hormone-Refractory Prostate Cancer

  2011cites this paper
• Characterisation of the co-chaperone small glutamine-rich tetratricopeptide repeat containing protein alpha as a regulator of androgen receptor activity in prostate cancer cells.

  2011cites this paper
• Cancer Therapy : Preclinical Molecular Chemotherapy and Chemotherapy : A New Front against Late-Stage Hormone-Refractory Prostate Cancer

  2011cites this paper
• Prognostic value of IL-6 in localized prostatic cancer.

  2010cites this paper
• Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival.

  2010cites this paper
• Heat shock proteins in prostate cancer: from tumorigenesis to the clinic

  2010cites this paper
• Novel post-digest isotope coded protein labeling method for phospho- and glycoproteome analysis.

  2010cites this paper
• Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer

  2010cites this paper
• Heat Shock Protein 90 as a Drug Target: Some Like It Hot

  2009cites this paper
• Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

  2008cites this paper
• Diagnostic 'Errors' in a Single Urogenital Pathology Unit

  2008cites this paper
• Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells

  2008cites this paper
• Interleukin-6, Interleukin-10 and Heat Shock Protein-90 Expression in Renal Epithelial Neoplasias and Surrounding Normal-Appearing Renal Parenchyma

  2007cites this paper
• Quantitative Immunohistochemical Analysis of Matrilysin 1 (MMP-7) in Various Renal Cell Carcinoma Subtypes

  2007cites this paper